Sanders Morris Harris LLC acquired a new position in shares of Eli Lilly And Co (NYSE:LLY) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 7,630 shares of the company’s stock, valued at approximately $1,252,000. Eli Lilly And Co comprises 0.6% of Sanders Morris Harris LLC’s investment portfolio, making the stock its 28th largest holding.
Several other institutional investors and hedge funds also recently made changes to their positions in the business. Franklin Resources Inc. grew its holdings in shares of Eli Lilly And Co by 8.7% in the fourth quarter. Franklin Resources Inc. now owns 7,579,405 shares of the company’s stock valued at $996,160,000 after purchasing an additional 607,932 shares in the last quarter. Prospera Financial Services Inc lifted its position in shares of Eli Lilly And Co by 2.9% during the 4th quarter. Prospera Financial Services Inc now owns 5,321 shares of the company’s stock worth $699,000 after buying an additional 150 shares during the last quarter. Pearl River Capital LLC lifted its holdings in shares of Eli Lilly And Co by 1,292.0% during the 4th quarter. Pearl River Capital LLC now owns 2,784 shares of the company’s stock worth $366,000 after acquiring an additional 2,584 shares during the period. Gladstone Institutional Advisory LLC acquired a new stake in Eli Lilly And Co during the 4th quarter worth approximately $231,000. Finally, Navellier & Associates Inc increased its position in Eli Lilly And Co by 11.1% during the 4th quarter. Navellier & Associates Inc now owns 2,000 shares of the company’s stock worth $263,000 after purchasing an additional 200 shares in the last quarter. Institutional investors and hedge funds own 77.44% of the company’s stock.
In other news, SVP Aarti S. Shah sold 2,000 shares of the business’s stock in a transaction that occurred on Tuesday, April 14th. The stock was sold at an average price of $150.00, for a total transaction of $300,000.00. Following the sale, the senior vice president now directly owns 19,087 shares in the company, valued at $2,863,050. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, major shareholder Lilly Endowment Inc sold 230,000 shares of the business’s stock in a transaction on Thursday, April 23rd. The shares were sold at an average price of $160.12, for a total value of $36,827,600.00. Following the completion of the sale, the insider now directly owns 112,593,158 shares in the company, valued at approximately $18,028,416,458.96. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 775,938 shares of company stock worth $126,523,306. Company insiders own 0.09% of the company’s stock.
Several brokerages have issued reports on LLY. Zacks Investment Research lowered their price objective on shares of Eli Lilly And Co to $156.00 in a research report on Wednesday, April 29th. JPMorgan Chase & Co. increased their target price on Eli Lilly And Co from $175.00 to $190.00 and gave the company an “overweight” rating in a research note on Wednesday, June 17th. Morgan Stanley cut Eli Lilly And Co from an “overweight” rating to an “equal weight” rating in a research note on Sunday, April 19th. Cowen raised their target price on Eli Lilly And Co from $145.00 to $160.00 and gave the company an “outperform” rating in a research note on Wednesday, April 15th. Finally, Goldman Sachs Group upgraded Eli Lilly And Co from a “buy” rating to a “conviction-buy” rating and set a $168.00 target price on the stock in a research note on Wednesday, March 11th. Four analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $168.58.
NYSE LLY traded down $0.76 during trading on Thursday, reaching $168.37. 30,463 shares of the company’s stock were exchanged, compared to its average volume of 4,003,722. Eli Lilly And Co has a fifty-two week low of $101.36 and a fifty-two week high of $169.82. The firm has a market capitalization of $161.76 billion, a PE ratio of 27.96, a P/E/G ratio of 1.55 and a beta of 0.26. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 4.37. The company’s fifty day simple moving average is $155.29 and its 200-day simple moving average is $145.04.
Eli Lilly And Co (NYSE:LLY) last announced its quarterly earnings data on Thursday, April 23rd. The company reported $1.75 EPS for the quarter, topping the Zacks’ consensus estimate of $1.48 by $0.27. Eli Lilly And Co had a return on equity of 194.18% and a net margin of 23.97%. The firm had revenue of $5.86 billion during the quarter, compared to analyst estimates of $5.48 billion. During the same period last year, the company posted $1.33 EPS. The business’s quarterly revenue was up 15.1% compared to the same quarter last year. Equities analysts forecast that Eli Lilly And Co will post 6.82 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Wednesday, June 10th. Investors of record on Friday, May 15th were paid a $0.74 dividend. This represents a $2.96 dividend on an annualized basis and a dividend yield of 1.76%. The ex-dividend date of this dividend was Thursday, May 14th. Eli Lilly And Co’s payout ratio is 49.01%.
About Eli Lilly And Co
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Further Reading: Derivative
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.